DrugPatentWatch Database Preview
Details for Patent: 9,198,882
» See Plans and Pricing
Which drugs does patent 9,198,882 protect, and when does it expire?
Patent 9,198,882 protects PROCYSBI and is included in two NDAs.
Protection for PROCYSBI has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has twenty-six patent family members in seventeen countries.
Summary for Patent: 9,198,882
| Title: | Enterically coated cysteamine, cystamine and derivatives thereof |
| Abstract: | The disclosure provides oral cysteamine and cystamine formulations useful for treating cystinosis and neurodegenerative diseases and disorders. The formulations provide controlled release compositions that improve quality of life and reduced side-effects. |
| Inventor(s): | Dohil; Ranjan (San Diego, CA), Schneider; Jerry (La Jolla, CA) |
| Assignee: | The Regents of the University of California (Oakland, CA) |
| Application Number: | 14/752,383 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,198,882 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Delivery; |
Drugs Protected by US Patent 9,198,882
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Horizon Pharma Usa | PROCYSBI | cysteamine bitartrate | GRANULE, DELAYED RELEASE;ORAL | 213491-001 | Feb 14, 2020 | RX | Yes | No | Start Trial | Start Trial | MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES | Start Trial | ||||
| Horizon Pharma Usa | PROCYSBI | cysteamine bitartrate | GRANULE, DELAYED RELEASE;ORAL | 213491-002 | Feb 14, 2020 | RX | Yes | Yes | Start Trial | Start Trial | MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES | Start Trial | ||||
| Horizon Pharma Usa | PROCYSBI | cysteamine bitartrate | CAPSULE, DELAYED RELEASE;ORAL | 203389-001 | Apr 30, 2013 | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | ||||
| Horizon Pharma Usa | PROCYSBI | cysteamine bitartrate | CAPSULE, DELAYED RELEASE;ORAL | 203389-002 | Apr 30, 2013 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,198,882
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2007210005 | Start Trial | |||
| Brazil | PI0707277 | Start Trial | |||
| Canada | 2640531 | Start Trial | |||
| Cyprus | 1113690 | Start Trial | |||
| Denmark | 1919458 | Start Trial | |||
| Denmark | 2535044 | Start Trial | |||
| Eurasian Patent Organization | 023971 | Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
